NEW YORK (GenomeWeb) – Veracyte said today that Highmark and Horizon Blue Cross Blue Shield of New Jersey issued positive coverage policies for the company's Afirma Gene Expression Classifier.

Both insurers are affiliated with Blue Cross Blue Shield and have classified Veracyte's genomic test as medically necessary for use in evaluating thyroid nodule fine needle aspiration biopsies that are indeterminate following traditional cytopathology review. The Afirma GEC test helps physicians determine which patients may need surgery as part of a thyroid cancer diagnosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.